Contact us for product
availability and pricing.

Welcome to InLighta BioSciences

Revolutionizing MRI
Contrast Agents for Disease
Detection and Tracking

What if you could detect cancer and other diseases earlier, faster and more easily?

You can with InLighta BioSciences’ patented MRI contrast agents

Current cancer and disease detection methods are unable to detect early-stage disease progression, reducing the likelihood of early treatment and interventions. With conventional methods being used today, many patients are only detected when it is almost too late.

With InLighta BioSciences, the hope of easier and earlier detection is a reality.
InLighta BioSciences offers precision Magnetic Resonance Imaging (pMRI) technology that addresses current deficiencies in other medical diagnostics making it possible for true early disease detection, faster monitoring disease progression, clearer opportunities to utilize image-guided intervention, and dramatically more effective evaluating drug delivery and therapeutic treatment.

Our Products/ Services

MRI Contrast Agents

InLighta is currently developing high-contrast agents for MR imaging. The ProCA® series of contrast agents includes both blood pool agents and targeted contrast agents for specific biomarkers.

01

ProCa® Series

(Protein-based Contrast Agents)

02

Blood Pool Agents

 

03

Targeted Contrast Agents

Latest News

Stay updated with the latest news and developments from InLighta BioSciences.

Explore More

InLighta BioSciences IN THE NEWS

Our Sponsors / Investors

Our Valuable Resources

Conflict of interest policy

Get in Touch

For additional information on products, services, or investment opportunities, please contact us using the form below.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Contact Information

InLighta BioSciences L.L.C.
Atlanta, GA 30303

Dr. Jenny J. Yang

Dr. Jina Qiao